Thermi®, an Almirall S.A. company, has been issued a medical device license from Health Canada to market the company's Thermi RF system for the treatment of dermal laxity. Thermi RF is the first and only device approved to treat dermal laxity in Canada and has been shown to effectively tighten loose skin.
Thermi RF, a temperature-controlled radiofrequency platform technology, was first approved in Canada in 2015 for electrocoagulation of soft tissue and nerve ablation. The technology has multiple applications, including ThermiTight, ThermiSmooth Face and ThermiRase. These treatments address loose skin and excess fat and wrinkles by using heat to precisely, gently and comfortably heat tissue to therapeutic temperatures.
"I have been treating patients with Thermi RF applications for a number of years now and have always seen outstanding results," said Dr. Jaggi Rao, a board-certified dermatologist and cosmetic surgeon at Alberta DermaSurgery Centre and Clinical Professor of Medicine, University of Alberta. "The approval by Health Canada of Thermi RF for dermal laxity is a testament to this innovative and versatile approach to skin tightening."
Thermi President Vlad Paul-Blanc said, "We are excited to announce the first-ever approval of a radiofrequency device for dermal laxity in Canada. We are especially pleased to achieve this milestone with impressive clinical data, and we look forward to continuing to expand our offerings in Canada, the US and beyond to ensure physicians and patients always have access to the most cutting-edge treatments."
Photos provided by Thermi.Next Story